General eligibility criteria for Greece
With a focus on research into natural biomolecules, an increasing number of companies are pioneering the development and clinical validation of specifically designed Nutraceuticals, supported by clinical studies. These products contribute both to patient stabilization, helping to protect against chronic and autoimmune diseases, and to the management of associated symptoms, ultimately contributing to an improved quality of life.
Nutraceuticals differ from dietary supplements in the following respects:
- Nutraceuticals complement the diet while, at the same time, aiming to prevent disease and/or support the human body during pharmacological treatment.
- Nutraceuticals may be used either as individual ingredients or as combinations of ingredients. Their use as a means of achieving the desired therapeutic outcome, with the fewest possible side effects compared with other therapeutic agents, is gaining increasing recognition.
Products submitted for consideration for the Prix Galien Greece Awards must have received an EOF (National Organization for Medicines) notification number at least five years prior to the application submission deadline. In other words, the products must have been commercially available on the Greek market for a minimum period of five years.
Qualitative criteria
Candidate products may belong to any therapeutic category. However, the Awards will be presented to products that contribute to improving the quality of life or saving lives, based on two criteria:
- What was the innovation throughout the scientific development of the product, its mechanism of action, and its clinical utility?
- What is the potential benefit to the future of medical science arising from the introduction of the product into clinical practice?
Only one winner will be selected in each Award category. However, in the event of a tie involving one or more candidates, the Jury shall have the right to designate a second winner under the Hors Prix distinction.
Eligibility criteria
- Originality of the product (i.e. not another conventional nutraceutical)
- Clinical studies supporting the beneficial properties of the product in specific health conditions
- Relevant broader studies, where applicable, targeting specific population groups
- Indicative formulations or delivery approaches designed to improve bioavailability
Specific eligibility criteria for Greece
Executive summary (up to 1 page)
A brief summary outlining the product’s key indications and the main elements of the nomination submission.
Product rationale and development (up to 3 pages)
This section should include:
- A description of how and why the product was developed
- Whether the product has a unique and specific therapeutic target
- Whether innovative techniques were employed in the development of the product
Clinical evaluation (up to 2 pages)
This section should describe a summary of the clinical development programme, including key information on the mechanism of action, dosing regimen, and design of the clinical trials.
The application may include information on no more than 10 peer-reviewed publications.
Conclusions (up to 1 page)
This section is optional. Applicants may wish to include conclusions highlighting the key advantages and benefits of the product.
Page format
The total length of the application for each Award category must not exceed 12 A4 pages, using 1.5 line spacing, 12-point Arial font, and 2 cm margins.
All supporting documentation and certificates must be submitted electronically together with the application.
Entry fee for nominations
For further information regarding the entry fee and the benefits included with your nomination for the “Best Nutraceutical Product”, please contact us at info@jpcom.gr or by telephone at +30 210 813 2828 or +30 210 813 2366.